Login Register Cart 0
Generic placeholder image

Current Pharmaceutical Design

Editor-in-Chief

ISSN (Print): 1381-6128
ISSN (Online): 1873-4286

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Systematic Review Article

Safety and Outcomes of Intravitreal Aflibercept in Diabetic Macular Edema – A Systematic Review

Author(s): Ana Maria Dascalu, Manfredi Rizzo, Ali A. Rizvi, Anca Pantea Stoian*, Raluca Claudia Iancu, Daniela Stana, Mihail Silviu Tudosie and Dragos Serban

Volume 28, Issue 21, 2022

Published on: 25 May, 2022

Page: [1758 - 1768] Pages: 11

DOI: 10.2174/1381612828666220425101030

Price: $65

Abstract

Background: Recent evidence on the role of vascular endothelial growth factor (VEGF) in the pathogenesis of ischemia and microvascular hyperpermeability leading to macular edema has brought anti-VEGF intravitreal therapy into the limelight.

Objective: We performed a systematic literature review focusing on the outcomes and safety of the intravitreal use of aflibercept in diabetic macular edema.

Methods: The studies documented cases with at least three consecutive intravitreal injections of aflibercept (IVA) repeated monthly with a follow-up period of at least one year. The outcomes were evaluated in terms of reported functional and anatomical improvement of the macula, as reflected by changes in visual acuity and macular thickness measured by Optical Coherence Tomography (OCT). In addition, for safety assessment, all reported local and general adverse effects were analyzed.

Results: All studies showed an overall significant anatomical and functional improvement. In patients with the 5 IVA monthly at the beginning of the therapy, the visual gain at 52 weeks varied widely between 5 and 18.9 EDRS letters, with a mean value of 9.48 letters. The higher gain was obtained in treatment naïve patients, with worse VA and increased CST at baseline. The lower gain was obtained in patients previously treated with anti- VEGF. Anti-Platelet Trialists' Collaboration-defined arterial thromboembolic events were not statistically different between the aflibercept group and the laser group.

Conclusion: Intravitreal aflibercept therapy provides significant improvement in visual acuity and a good safety profile. Randomized studies are needed to document the optimal frequency of intravitreal injections for optimal treatment.

Keywords: Aflibercept, anti-VEFG agents, diabetic macular edema, laser therapy, macular thickness, ocular adverse events, outcomes, systemic adverse events.

« Previous Next »
[1]
Poti JM, Braga B, Qin B. Ultra-processed food intake and obesity: What really matters for health-processing or nutrient content? Curr Obes Rep 2017; 6(4): 420-31.
[http://dx.doi.org/10.1007/s13679-017-0285-4 ] [PMID: 29071481]
[2]
Sá-Marta M, Marques M, Figueiredo J, et al. Dietary imbalance between natural and added nutrient sources is associated with higher fat mass in young non-obese individuals. Diabetology 2021; 2(2): 95-106.
[http://dx.doi.org/10.3390/diabetology2020008]
[3]
Cho NH, Shaw JE, Karuranga S, et al. IDF diabetes atlas: Global estimates of diabetes prevalence for 2017 and projections for 2045. Diabetes Res Clin Pract 2018; 138: 271-81.
[http://dx.doi.org/10.1016/j.diabres.2018.02.023 ] [PMID: 29496507]
[4]
Khan MAB, Hashim MJ, King JK, Govender RD, Mustafa H, Al Kaabi J. Epidemiology of type 2 diabetes - global burden of disease and forecasted trends. J Epidemiol Glob Health 2020; 10(1): 107-11.
[http://dx.doi.org/10.2991/jegh.k.191028.001 ] [PMID: 32175717]
[5]
Lee R, Wong TY, Sabanayagam C. Epidemiology of diabetic retinopathy, diabetic macular edema and related vision loss. Eye Vis (Lond) 2015; 30: 2-17.
[http://dx.doi.org/10.1186/s40662-015-0026-2]
[6]
Zheng Y, He M, Congdon N. The worldwide epidemic of diabetic retinopathy. Indian J Ophthalmol 2012; 60(5): 428-31.
[http://dx.doi.org/10.4103/0301-4738.100542 ] [PMID: 22944754]
[7]
Laiginhas R, Madeira C, Lopes M, et al. Risk factors for prevalent diabetic retinopathy and proliferative diabetic retinopathy in type 1 diabetes. Endocrine 2019; 66(2): 201-9.
[http://dx.doi.org/10.1007/s12020-019-02047-z ] [PMID: 31407162]
[8]
Schreur V, van Asten F, Ng H, et al. Risk factors for development and progression of diabetic retinopathy in Dutch patients with type 1 diabetes mellitus. Acta Ophthalmol 2018; 96(5): 459-64.
[http://dx.doi.org/10.1111/aos.13815 ] [PMID: 30188024]
[9]
Serban D, Papanas N, Dascalu AM, et al. Diabetic retinopathy in patients with diabetic foot ulcer: A systematic review. Int J Low Extrem Wounds 2021; 20(2): 98-103.
[http://dx.doi.org/10.1177/1534734620982237 ] [PMID: 33353439]
[10]
Romero-Aroca P, Navarro-Gil R, Valls-Mateu A, Sagarra-Alamo R, Moreno-Ribas A, Soler N. Differences in incidence of diabetic retinopathy between type 1 and 2 diabetes mellitus: A nine-year follow-up study. Br J Ophthalmol 2017; 101(10): 1346-51.
[http://dx.doi.org/10.1136/bjophthalmol-2016-310063 ] [PMID: 28270484]
[11]
Nathan DM. DER Group. The diabetes control and complications trial/epidemiology of diabetes interventions and complications study at 30 years: Overview. Diabetes Care 2014; 37(1): 9-16.
[http://dx.doi.org/10.2337/dc13-2112 ] [PMID: 24356592]
[12]
Chamard C. Ten-year incidence and progression of diabetic retinopathy in type 1 and type 2 diabetes in France: The OPHDIAT study. Invest Ophthalmol Vis Sci 2019; 60(9): 1102.
[13]
Liew G, Wong VW, Ho IV. Mini review: Changes in the incidence of and progression to proliferative and sight-threatening diabetic retinopathy over the last 30 years. Ophthalmic Epidemiol 2017; 24(2): 73-80.
[http://dx.doi.org/10.1080/09286586.2016.1259638 ] [PMID: 28102748]
[14]
Coughlin BA, Feenstra DJ, Mohr S. Müller cells and diabetic retinopathy. Vision Res 2017; 139: 93-100.
[http://dx.doi.org/10.1016/j.visres.2017.03.013 ] [PMID: 28866025]
[15]
Sun JK, Jampol LM. The diabetic retinopathy clinical research network (DRCR.net) and its contributions to the treatment of diabetic retinopathy. Ophthalmic Res 2019; 62(4): 225-30.
[http://dx.doi.org/10.1159/000502779 ] [PMID: 31554001]
[16]
Avery RL, Castellarin AA, Steinle NC, et al. Systemic pharmacokinetics and pharmacodynamics of intravitreal aflibercept, bevacizumab, and ranibizumab. Retina 2017; 37(10): 1847-58.
[http://dx.doi.org/10.1097/IAE.0000000000001493 ] [PMID: 28106709]
[17]
Avery RL. What is the evidence for systemic effects of intravitreal anti-VEGF agents, and should we be concerned? Br J Ophthalmol 2014; 98(Suppl. 1): i7-i10.
[http://dx.doi.org/10.1136/bjophthalmol-2013-303844 ] [PMID: 24326326]
[18]
Chen HX, Cleck JN. Adverse effects of anticancer agents that target the VEGF pathway. Nat Rev Clin Oncol 2009; 6(8): 465-77.
[http://dx.doi.org/10.1038/nrclinonc.2009.94 ] [PMID: 19581909]
[19]
Korobelnik JF, Do DV, Schmidt-Erfurth U, et al. Intravitreal aflibercept for diabetic macular edema. Ophthalmology 2014; 121(11): 2247-54.
[http://dx.doi.org/10.1016/j.ophtha.2014.05.006 ] [PMID: 25012934]
[20]
Brown DM, Schmidt-Erfurth U, Do DV, et al. Intravitreal aflibercept for diabetic macular edema: 100-week results from the VISTA and VIVID studies. Ophthalmology 2015; 122(10): 2044-52.
[http://dx.doi.org/10.1016/j.ophtha.2015.06.017 ] [PMID: 26198808]
[21]
Heier JS, Korobelnik JF, Brown DM, et al. Intravitreal aflibercept for diabetic macular edema: 148-Week results from the VISTA and VIVID studies. Ophthalmology 2016; 123(11): 2376-85.
[http://dx.doi.org/10.1016/j.ophtha.2016.07.032 ] [PMID: 27651226]
[22]
Terasaki H, Shiraki K, Ohji M, et al. Efficacy and safety outcomes of intravitreal aflibercept focusing on patients with diabetic macular edema from Japan. Retina 2019; 39(5): 938-47.
[http://dx.doi.org/10.1097/IAE.0000000000002100 ] [PMID: 29470308]
[23]
Do DV, Nguyen QD, Vitti R, et al. Intravitreal aflibercept injection in diabetic macular edema patients with and without prior anti-vascular endothelial growth factor treatment: Outcomes from the phase 3 program. Ophthalmology 2016; 123(4): 850-7.
[http://dx.doi.org/10.1016/j.ophtha.2015.11.008 ] [PMID: 26832658]
[24]
Dhoot DS, Baker K, Saroj N, et al. Baseline factors affecting changes in diabetic retinopathy severity scale score after intravitreal aflibercept or laser for diabetic macular edema: Post hoc analyses from VISTA and VIVID. Ophthalmology 2018; 125(1): 51-6.
[http://dx.doi.org/10.1016/j.ophtha.2017.06.029 ] [PMID: 28764888]
[25]
Staurenghi G, Feltgen N, Arnold JJ, et al. VIVID-DME and VISTA-DME study investigators. Impact of baseline diabetic retinopathy severity scale scores on visual outcomes in the VIVID-DME and VISTA-DME studies. Br J Ophthalmol 2018; 102(7): 954-8.
[http://dx.doi.org/10.1136/bjophthalmol-2017-310664 ] [PMID: 29051325]
[26]
Baker CW, Glassman AR, Beaulieu WT, et al. DRCR Retina Network. Effect of initial management with aflibercept vs. laser photocoagulation vs. observation on vision loss among patients with diabetic macular edema involving the center of the macula and good visual acuity: A randomized clinical trial. JAMA 2019; 321(19): 1880-94.
[http://dx.doi.org/10.1001/jama.2019.5790 ] [PMID: 31037289]
[27]
Wells JA, Glassman AR, Ayala AR, et al. Diabetic Retinopathy Clinical Research Network. Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema. N Engl J Med 2015; 372(13): 1193-203.
[http://dx.doi.org/10.1056/NEJMoa1414264 ] [PMID: 25692915]
[28]
Wells JA, Glassman AR, Ayala AR, et al. Diabetic retinopathy clinical research network. aflibercept, bevacizumab, or ranibizumab for diabetic macular edema: Two-year results from a comparative effectiveness randomized clinical trial. Ophthalmology 2016; 123(6): 1351-9.
[http://dx.doi.org/10.1016/j.ophtha.2016.02.022 ] [PMID: 26935357]
[29]
Bressler NM, Beaulieu WT, Maguire MG, et al. Diabetic retinopathy clinical research network. Early response to anti-vascular endothelial growth factor and two-year outcomes among eyes with diabetic macular edema in protocol T. Am J Ophthalmol 2018; 195: 93-100.
[http://dx.doi.org/10.1016/j.ajo.2018.07.030 ] [PMID: 30077569]
[30]
Wells JA, Glassman AR, Jampol LM, et al. Diabetic retinopathy clinical research network. association of baseline visual acuity and retinal thickness with 1-year efficacy of aflibercept, bevacizumab, and ranibizumab for diabetic macular edema. JAMA Ophthalmol 2016; 134(2): 127-34.
[http://dx.doi.org/10.1001/jamaophthalmol.2015.4599 ] [PMID: 26605836]
[31]
Bressler NM, Beaulieu WT, Glassman AR, et al. Diabetic retinopathy clinical research network. persistent macular thickening following intravitreous aflibercept, bevacizumab, or ranibizumab for central-involved diabetic macular edema with vision impairment: A secondary analysis of a randomized clinical trial. JAMA Ophthalmol 2018; 136(3): 257-69.
[http://dx.doi.org/10.1001/jamaophthalmol.2017.6565 ] [PMID: 29392288]
[32]
Salimi A, Vila N, Modabber M, Kapusta M. One-year outcomes of Aflibercept for refractory diabetic macular edema in Bevacizumab nonresponders. Indian J Ophthalmol 2021; 69(2): 360-7.
[http://dx.doi.org/10.4103/ijo.IJO_459_20 ] [PMID: 33463593]
[33]
Garweg JG, Stefanickova J, Hoyng C, et al. AQUA investigators. Vision-related quality of life in patients with diabetic macular edema treated with intravitreal aflibercept: The AQUA study. Ophthalmol Retina 2019; 3(7): 567-75.
[http://dx.doi.org/10.1016/j.oret.2019.03.012 ] [PMID: 31080168]
[34]
Pak KY, Shin JP, Kim HW, et al. One-year results of treatment of diabetic macular edema with aflibercept using the treat-and-extend dosing regimen: The VIBIM study. Ophthalmologica 2020; 243(4): 255-62.
[http://dx.doi.org/10.1159/000504753 ] [PMID: 31914437]
[35]
Kim YC, Shin JP, Pak KY, et al. Two-year outcomes of the treat-and-extend regimen using aflibercept for treating diabetic macular oedema. Sci Rep 2020; 10(1): 22030.
[http://dx.doi.org/10.1038/s41598-020-78954-3 ] [PMID: 33328488]
[36]
Cakir A, Erden B, Bolukbasi S, et al. Three versus five intravitreal aflibercept injections as the initial loading phase in the treatment of diabetic macular edema: One-year results. Arq Bras Oftalmol 2020; 83(5): 396-401.
[PMID: 33084817]
[37]
Kern C, Schiefelbein J, Fu DJ, et al. Two year visual acuity and structural outcomes in patients with diabetic macular oedema treated with intravitreal aflibercept - a retrospective cohort study. Clin Ophthalmol 2020; 14: 533-41.
[http://dx.doi.org/10.2147/OPTH.S237586 ] [PMID: 32161438]
[38]
Lukic M, Williams G, Shalchi Z, et al. Intravitreal aflibercept for diabetic macular oedema: Moorfields’ real-world 12-month visual acuity and anatomical outcomes. Eur J Ophthalmol 2020; 30(3): 557-62.
[http://dx.doi.org/10.1117/1120672119833270. ] [PMID: 30808179]
[39]
Korobelnik JF, Daien V, Faure C, et al. Real-world outcomes following 12 months of intravitreal aflibercept monotherapy in patients with diabetic macular edema in France: Results from the APOLLON study. Graefes Arch Clin Exp Ophthalmol 2020; 258(3): 521-8.
[http://dx.doi.org/10.1007/s00417-019-04592-9 ] [PMID: 31894377]
[40]
Ferris FL III, Maguire MG, Glassman AR, Ying GS, Martin DF. Evaluating effects of switching anti-vascular endothelial growth factor drugs for age-related macular degeneration and diabetic macular edema. JAMA Ophthalmol 2017; 135(2): 145-9.
[http://dx.doi.org/10.1001/jamaophthalmol.2016.4820 ] [PMID: 28006042]
[41]
Bahrami B, Hong T, Zhu M, Schlub TE, Chang A. Switching therapy from bevacizumab to aflibercept for the management of persistent diabetic macular edema. Graefes Arch Clin Exp Ophthalmol 2017; 255(6): 1133-40.
[http://dx.doi.org/10.1007/s00417-017-3624-y ] [PMID: 28238195]
[42]
Chen YY, Chang PY, Wang JK. Intravitreal aflibercept for patients with diabetic macular edema refractory to bevacizumab or ranibizumab: Analysis of response to aflibercept. Asia Pac J Ophthalmol (Phila) 2017; 6(3): 250-5.
[PMID: 28436640]
[43]
Bahrami B, Hong T, Schlub TE, Chang AA. AFLIBERCEPT FOR PERSISTENT DIABETIC MACULAR EDEMA: Forty-Eight-Week Outcomes. Retina 2019; 39(1): 61-8.
[http://dx.doi.org/10.1097/IAE.0000000000002253 ] [PMID: 30015767]
[44]
Rahimy E, Shahlaee A, Khan MA, et al. Conversion to aflibercept after prior anti-VEGF therapy for persistent diabetic macular edema. Am J Ophthalmol 2016; 164: 118-27.e2.
[http://dx.doi.org/10.1016/j.ajo.2015.12.030 ] [PMID: 26748058]
[45]
Lechner J, O’Leary OE, Stitt AW. The pathology associated with diabetic retinopathy. Vision Res 2017; 139: 7-14.
[http://dx.doi.org/10.1016/j.visres.2017.04.003 ] [PMID: 28412095]
[46]
Romero-Aroca P, Baget-Bernaldiz M, Pareja-Rios A, Lopez-Galvez M, Navarro-Gil R, Verges R. Diabetic macular edema pathophysiology: Vasogenic versus inflammatory. J Diabetes Res 2016; 2016: 2156273.
[http://dx.doi.org/10.1155/2016/2156273 ] [PMID: 27761468]
[47]
Wang J, Chen S, Jiang F, et al. Vitreous and plasma VEGF levels as predictive factors in the progression of proliferative diabetic retinopathy after vitrectomy. PLoS One 2014; 9(10): e110531.
[http://dx.doi.org/10.1371/journal.pone.0110531 ] [PMID: 25329921]
[48]
Zhou Z, Ju H, Sun M, Chen H. Serum vascular endothelial growth factor levels correlate with severity of retinopathy in diabetic patients: A systematic review and meta-analysis. Dis Markers 2019; 2019: 9401628.
[http://dx.doi.org/10.1155/2019/9401628 ] [PMID: 31019585]
[49]
Woolard J, Bevan HS, Harper SJ, Bates DO. Molecular diversity of VEGF-A as a regulator of its biological activity. Microcirculation 2009; 16(7): 572-92.
[http://dx.doi.org/10.1080/10739680902997333 ] [PMID: 19521900]
[50]
Sumner G, Georgaros C, Rafique A, et al. Anti-VEGF drug interference with VEGF quantitation in the R&D systems human quantikine VEGF ELISA kit. Bioanalysis 2019; 11(5): 381-92.
[http://dx.doi.org/10.4155/bio-2018-0096 ] [PMID: 30892063]
[51]
Wu WC, Lien R, Liao PJ, et al. Serum levels of vascular endothelial growth factor and related factors after intravitreous bevacizumab injection for retinopathy of prematurity. JAMA Ophthalmol 2015; 133(4): 391-7.
[http://dx.doi.org/10.1001/jamaophthalmol.2014.5373 ] [PMID: 25569026]
[52]
Kusumanto YH, Meijer C, Dam W, Mulder NH, Hospers GA. Circulating vascular endothelial growth factor (VEGF) levels in advanced stage cancer patients compared to normal controls and diabetes mellitus patients with critical ischemia. Drug Target Insights 2007; 2(1): 105-9.
[http://dx.doi.org/10.33393/dti.2007.2025 ] [PMID: 21901067]
[53]
Shibuya M. Vascular endothelial growth factor (VEGF) and its receptor (VEGFR) signaling in angiogenesis: A crucial target for anti- and pro-angiogenic therapies. Genes Cancer 2011; 2(12): 1097-105.
[http://dx.doi.org/10.1177/1947601911423031 ] [PMID: 22866201]
[54]
Jampol LM, Glassman AR, Liu D, et al. Diabetic retinopathy clinical research network. Plasma vascular endothelial growth factor concentrations after intravitreous anti-vascular endothelial growth factor therapy for diabetic macular edema. Ophthalmology 2018; 125(7): 1054-63.
[http://dx.doi.org/10.1016/j.ophtha.2018.01.019 ] [PMID: 29525602]
[55]
Hirano T, Toriyama Y, Iesato Y, Imai A, Murata T. Changes in plasma vascular endothelial growth factor level after intravitreal injection of bevacizumab, aflibercept, or ranibizumab for diabetic macular edema. Retina 2018; 38(9): 1801-8.
[http://dx.doi.org/10.1097/IAE.0000000000002004 ] [PMID: 29280940]
[56]
Sugimoto M, Wakamatsu Y, Miyata R, et al. Expression of vascular infarction-related molecules after anti-vascular endothelium growth factor treatment for diabetic macular edema. Sci Rep 2019; 9(1): 12373.
[http://dx.doi.org/10.1038/s41598-019-48869-9 ] [PMID: 31451777]
[57]
George ML, Eccles SA, Tutton MG, Abulafi AM, Swift RI. Correlation of plasma and serum vascular endothelial growth factor levels with platelet count in colorectal cancer: Clinical evidence of platelet scavenging? Clin Cancer Res 2000; 6(8): 3147-52.
[PMID: 10955796]
[58]
Urias EA, Urias GA, Monickaraj F, McGuire P, Das A. Novel therapeutic targets in diabetic macular edema: Beyond VEGF. Vision Res 2017; 139: 221-7.
[http://dx.doi.org/10.1016/j.visres.2017.06.015 ] [PMID: 28993218]
[59]
Lazzara F, Fidilio A, Platania CBM, et al. Aflibercept regulates retinal inflammation elicited by high glucose via the PlGF/ERK pathway. Biochem Pharmacol 2019; 168: 341-51.
[http://dx.doi.org/10.1016/j.bcp.2019.07.021 ] [PMID: 31351870]
[60]
Hardiansyah D, Ng CM. Effects of the FcRn developmental pharmacology on the pharmacokinetics of therapeutic monoclonal IgG antibody in pediatric subjects using minimal physiologically-based pharmacokinetic modelling. MAbs 2018; 10(7): 1144-56.
[http://dx.doi.org/10.1080/19420862.2018.1494479 ] [PMID: 29969360]
[61]
de Lima Farah J, Sano R, Maugéri IML, et al. Evaluation of aflibercept and ziv-aflibercept binding affinity to vascular endothelial growth factor, stability and sterility after compounding. Int J Retina Vitreous 2018; 24: 4-39.
[http://dx.doi.org/10.1186/s40942-018-0143-x]
[62]
MacDonald DA, Martin J, Muthusamy KK, et al. Aflibercept exhibits VEGF binding stoichiometry distinct from bevacizumab and does not support formation of immune-like complexes. Angiogenesis 2016; 19(3): 389-406.
[http://dx.doi.org/10.1007/s10456-016-9515-8 ] [PMID: 27234973]
[63]
Yoshida S, Murakami T, Nozaki M, et al. Review of clinical studies and recommendation for a therapeutic flow chart for diabetic macular edema. Graefes Arch Clin Exp Ophthalmol 2021; 259(4): 815-36.
[http://dx.doi.org/10.1007/s00417-020-04936-w ] [PMID: 32997288]
[64]
García-Quintanilla L, Luaces-Rodríguez A, Gil-Martínez M, et al. Pharmacokinetics of intravitreal anti-VEGF drugs in age-related macular degeneration. Pharmaceutics 2019; 11(8): 365.
[http://dx.doi.org/10.3390/pharmaceutics11080365 ] [PMID: 31370346]
[65]
Fogli S, Mogavero S, Egan CG, Del Re M, Danesi R. Pathophysiology and pharmacological targets of VEGF in diabetic macular edema. Pharmacol Res 2016; 103: 149-57.
[http://dx.doi.org/10.1016/j.phrs.2015.11.003 ] [PMID: 26607863]
[66]
Christoforidis JB, Williams MM, Kothandaraman S, Kumar K, Epitropoulos FJ, Knopp MV. Pharmacokinetic properties of intravitreal I-124-aflibercept in a rabbit model using PET/CT. Curr Eye Res 2012; 37(12): 1171-4.
[http://dx.doi.org/10.3109/02713683.2012.727521 ] [PMID: 22991959]
[67]
Park SJ, Choi Y, Na YM, et al. Intraocular pharmacokinetics of intravitreal aflibercept (Eylea) in a rabbit model. Invest Ophthalmol Vis Sci 2016; 57(6): 2612-7.
[http://dx.doi.org/10.1167/iovs.16-19204 ] [PMID: 27258433]
[68]
Bakri SJ, Snyder MR, Reid JM, Pulido JS, Ezzat MK, Singh RJ. Pharmacokinetics of intravitreal ranibizumab (Lucentis). Ophthalmology 2007; 114(12): 2179-82.
[http://dx.doi.org/10.1016/j.ophtha.2007.09.012 ] [PMID: 18054637]
[69]
Bakri SJ, Snyder MR, Reid JM, Pulido JS, Singh RJ. Pharmacokinetics of intravitreal bevacizumab (Avastin). Ophthalmology 2007; 114(5): 855-9.
[http://dx.doi.org/10.1016/j.ophtha.2007.01.017 ] [PMID: 17467524]
[70]
Papadopoulos N, Martin J, Ruan Q, et al. Binding and neutralization of vascular endothelial growth factor (VEGF) and related ligands by VEGF Trap, ranibizumab and bevacizumab. Angiogenesis 2012; 15(2): 171-85.
[http://dx.doi.org/10.1007/s10456-011-9249-6 ] [PMID: 22302382]
[71]
Antithrombotic Trialists’ Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002; 324(7329): 71-86.
[http://dx.doi.org/10.1136/bmj.324.7329.71 ] [PMID: 11786451]
[72]
Muftuoglu IK, Arcinue CA, Tsai FF, et al. Long-term results of Pro Re Nata regimen of aflibercept treatment in persistent neovascular age-related macular degeneration. Am J Ophthalmol 2016; 167: 1-9.
[http://dx.doi.org/10.1016/j.ajo.2016.03.038 ] [PMID: 27049000]
[73]
Augsburger M, Sarra GM, Imesch P. Treat and extend versus pro re nata regimens of ranibizumab and aflibercept in neovascular age-related macular degeneration: A comparative study. Graefes Arch Clin Exp Ophthalmol 2019; 257(9): 1889-95.
[http://dx.doi.org/10.1007/s00417-019-04404-0 ] [PMID: 31256237]
[74]
Schmidt-Erfurth U, Garcia-Arumi J, Bandello F, et al. Guidelines for the Management of Diabetic Macular Edema by the European Society of Retina Specialists (EURETINA). Ophthalmologica 2017; 237(4): 185-222.
[http://dx.doi.org/10.1159/000458539 ] [PMID: 28423385]
[75]
Abouhussein MA, Gomaa AR. Aflibercept plus micropulse laser versus aflibercept monotherapy for diabetic macular edema: 1-year results of a randomized clinical trial. Int Ophthalmol 2020; 40(5): 1147-54.
[http://dx.doi.org/10.1007/s10792-019-01280-9 ] [PMID: 31919773]
[76]
Kanar HS, Arsan A, Altun A, Akı SF, Hacısalihoglu A. Can subthreshold micropulse yellow laser treatment change the anti-vascular endothelial growth factor algorithm in diabetic macular edema? A randomized clinical trial. Indian J Ophthalmol 2020; 68(1): 145-51.
[http://dx.doi.org/10.4103/ijo.IJO_350_19 ] [PMID: 31856493]
[77]
Khattab AM, Hagras SM. AbdElhamid A, Torky MA, Awad EA, Abdelhameed AG. Aflibercept with adjuvant micropulsed yellow laser versus aflibercept monotherapy in diabetic macular edema. Graefes Arch Clin Exp Ophthalmol 2019; 257(7): 1373-80.
[http://dx.doi.org/10.1007/s00417-019-04355-6 ] [PMID: 31127381]
[78]
Xiao K, Li FZ, Liang SZ, Wang J, Qian C, Wan GM. Efficacy of conversion to aflibercept for diabetic macular edema previously refractory to bevacizumab or ranibizumab: A meta-analysis of high-quality nonrandomized studies. Ann Pharmacother 2020; 54(8): 750-6.
[http://dx.doi.org/10.1177/1060028020904358 ] [PMID: 32005079]
[79]
Laiginhas R, Silva MI, Rosas V, et al. Aflibercept in diabetic macular edema refractory to previous bevacizumab: Outcomes and predictors of success. Graefes Arch Clin Exp Ophthalmol 2018; 256(1): 83-9.
[http://dx.doi.org/10.1007/s00417-017-3836-1 ] [PMID: 29082448]
[80]
Ibrahim WS, Eldaly ZH, Saleh MG, Rateb MF, Aldoghaimy AH. Switching to aflibercept in diabetic macular edema after unsatisfactory response to other anti-vascular endothelial growth factor drugs. Korean J Ophthalmol 2019; 33(2): 122-30.
[http://dx.doi.org/10.3341/kjo.2018.0037 ] [PMID: 30977321]
[81]
Wilkins CS, Sobol EK, Lema GM, Lee JG, Rosen RB, Deobhakta A. Intravitreal dexamethasone insert in diabetic macular edema super-refractory to anti-vascular endothelial growth factor therapy. Eur J Ophthalmol 2021; 23: 11206721211004391.
[http://dx.doi.org/10.1177/11206721211004391 ] [PMID: 33757333]
[82]
Hernández-Bel L, Cervera-Taulet E, Navarro-Palop C, Castro-Navarro V, Chiarri-Toumit C, Montero-Hernández J. Sequential dexamethasone and aflibercept treatment in patients with diabetic macular edema: Structural and functional outcomes at 52 weeks. Ophthalmologica 2019; 241(2): 98-104.
[http://dx.doi.org/10.1159/000489345 ] [PMID: 29996128]

Rights & Permissions Print Cite
Article Metrics
24
1
© 2024 Bentham Science Publishers | Privacy Policy